B97.7 is a supplementary ICD-10-CM code used to identify Human Papillomavirus (HPV) as the specific viral etiology for a wide range of pathological conditions classified in other chapters of the manual. As a member of the Papillomaviridae family, HPV is a non-enveloped, double-stranded DNA virus that primarily infects squamous epithelial cells. This code is never used as a primary diagnosis but serves as a mandatory or elective 'use additional code' entry to provide clinical specificity for conditions such as malignant neoplasms of the cervix, vulva, vagina, anus, and oropharynx, as well as benign conditions like condyloma acuminatum (genital warts) or recurrent respiratory papillomatosis. Identifying the HPV status is clinically critical for determining prognosis, specifically in head and neck cancers, where HPV-positive status generally correlates with better treatment outcomes compared to tobacco-associated malignancies.
Sequencing Requirement: B97.7 is a supplemental code and must never be used as the primary diagnosis. Always code the manifestation, such as cervical dysplasia or oropharyngeal cancer, first.
Example: Patient with biopsy-confirmed High-grade Squamous Intraepithelial Lesion (HSIL) of the cervix (N87.1). Laboratory PCR testing identifies Human papillomavirus (HPV) as the causative agent. Assessment: HSIL of cervix caused by HPV. Plan: Referral for LEEP procedure. Billing focuses on the specific grade of dysplasia (N87.1) followed by B97.7 to identify the viral etiology. Risk adjustment accounts for the severity of the precancerous lesion and its viral driver.
Billing Focus: Identify the primary manifestation code first followed by B97.7; ensure the manifestation is documented as being caused by HPV.
Document High-Risk vs Low-Risk Strains: While B97.7 is a general code, clinical documentation should specify if high-risk strains (e.g., 16, 18) are present, as this influences the risk adjustment for malignant progression.
Example: 62-year-old male presenting with squamous cell carcinoma of the tonsil (C09.9). Pathology reports confirm p16-positive status, indicating Human papillomavirus (HPV) as the primary driver. Patient is currently undergoing radiation therapy. Billing includes C09.9 with B97.7 as a secondary code to denote HPV causation. Risk adjustment is heavily influenced by the p16-positive status indicating high-risk HPV etiology.
Billing Focus: Clarify the causal relationship between the HPV infection and the specific neoplastic site.
Specific Manifestation Details: Document the exact anatomical location and the nature of the lesion (e.g., wart, dysplasia, carcinoma) to support the primary ICD-10-CM code.
Example: Patient presents with multiple condyloma acuminatum of the vulva (A63.0). Clinical evaluation confirms Human papillomavirus (HPV) as the cause. Lesions are located on the bilateral labia majora. Management includes cryotherapy. Billing focuses on A63.0 with B97.7. Risk adjustment is stable based on the localized infectious manifestation.
Billing Focus: Laterality and specific anatomical location of the primary manifestation (e.g., vulva vs. perianal).
Identify Comorbidities and Immune Status: Document if the patient is immunocompromised (e.g., HIV, transplant recipient), as HPV-related diseases are more aggressive in these populations.
Example: Patient with history of kidney transplant (Z94.0) and chronic immunosuppressant use presents with biopsy-proven severe cervical dysplasia (N87.2) caused by Human papillomavirus (B97.7). The immunosuppressed state (D89.811) significantly increases the complexity of management. Billing includes N87.2, B97.7, and D89.811. Risk adjustment is high due to the interaction between immunosuppression and HPV-related dysplasia.
Billing Focus: Linkage between the patient's immune status and the persistence or severity of the HPV-related disease.
Linkage Statements: Use definitive language such as 'due to' or 'caused by' to establish the relationship between HPV and the disease, ensuring B97.7 can be accurately applied.
Example: A 45-year-old female presents for follow-up of focal epithelial hyperplasia (Heck's disease) of the oral mucosa (K13.29). This condition is documented as caused by Human papillomavirus (B97.7). No evidence of malignancy. Billing utilizes K13.29 followed by B97.7. Risk adjustment relies on the chronic nature of the viral-driven oral lesion.
Billing Focus: Clear causal linkage between the virus and the oral manifestation.
Used for routine follow-up of benign HPV lesions or mild dysplasia with low complexity management.
Used when managing HPV-related conditions that require detailed treatment plans, such as coordinating surgical oncology or specialty referrals.
The standard procedure for diagnosing cervical dysplasia caused by HPV.
Common treatment for cutaneous or mucosal HPV lesions to prevent malignant transformation.
Definitive treatment for high-grade cervical intraepithelial neoplasia (CIN II/III).
Used to evaluate anal intraepithelial neoplasia (AIN) in high-risk patients.
The primary laboratory test used to identify HPV as the causative agent for coding B97.7.
Primary treatment for Recurrent Respiratory Papillomatosis (RRP).
Diagnostic procedure for vulvar intraepithelial neoplasia (VIN).
Preventive measure directly related to the prevention of conditions coded with B97.7.